Immunotherapy in recent years has solidified its position as the fourth pillar of cancer treatment alongside surgery, chemotherapy, and radiation. Although in its infancy, when compared with these other conventional therapeutic strategies, immunotherapy has provided a chance for prolonged survival, and in some cases even cure, for patients who previously would have been given a terminal diagnosis. In head and neck cancer in particular, the advent of antiprogrammed cell death protein 1 (anti-PD-1) immune checkpoint blockade has shown modest response rates in patients with recurrent or metastatic mucosal squamous cell carcinoma.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου